Cross-national drug price comparisons with economic weights in external reference pricing in Germany

Joerg Mahlich, Joern Sindern, Moritz Suppliet

Research output: Contribution to journalReview articleScientificpeer-review

Abstract

Background: Since 2012, the pharmaceutical reimbursement legislation in Germany has been applying external reference pricing that uses country-specific economic weights for foreign prices. However, the law does not specify technical details. Therefore, we develop a proposal how national income weights can be taken into consideration.

Areas covered: We develop weighting schemes that draw on gross domestic product per capita and adjust for purchasing power parities, and exchange rates. In a second step, we populate the weighting schemes with economic data as well as with the price data for a pharmaceutical product (abiraterone acetate). Weighting the price of abiraterone acetate by gross domestic product per capita indicates potential price differentials of up to 43 percentage points across European prices in the German basket.

Expert commentary: The weighting of foreign pharmaceutical prices by economic indicators, i.e. gross domestic product per capita, can capture economic differences across countries. It would also allow for differential Ramsey pricing which might foster innovation.
Original languageEnglish
Pages (from-to)37-43
JournalExpert Review of Pharmacoeconomics & Outcomes Research
Volume19
Issue number1
DOIs
Publication statusPublished - Jan 2019

Fingerprint

Germany
Weights and Measures
Pharmaceutical Preparations
Pharmaceutical Economics
Parity
Legislation
Abiraterone Acetate

Keywords

  • pharmaceutical prices
  • reference pricing
  • innovation
  • cross-country price comparisons
  • health policy
  • health insurance
  • regulation

Cite this

@article{4c7d722a49824267b20f28177e3211ae,
title = "Cross-national drug price comparisons with economic weights in external reference pricing in Germany",
abstract = "Background: Since 2012, the pharmaceutical reimbursement legislation in Germany has been applying external reference pricing that uses country-specific economic weights for foreign prices. However, the law does not specify technical details. Therefore, we develop a proposal how national income weights can be taken into consideration.Areas covered: We develop weighting schemes that draw on gross domestic product per capita and adjust for purchasing power parities, and exchange rates. In a second step, we populate the weighting schemes with economic data as well as with the price data for a pharmaceutical product (abiraterone acetate). Weighting the price of abiraterone acetate by gross domestic product per capita indicates potential price differentials of up to 43 percentage points across European prices in the German basket.Expert commentary: The weighting of foreign pharmaceutical prices by economic indicators, i.e. gross domestic product per capita, can capture economic differences across countries. It would also allow for differential Ramsey pricing which might foster innovation.",
keywords = "pharmaceutical prices, reference pricing, innovation, cross-country price comparisons, health policy, health insurance, regulation",
author = "Joerg Mahlich and Joern Sindern and Moritz Suppliet",
year = "2019",
month = "1",
doi = "10.1080/14737167.2019.1527221",
language = "English",
volume = "19",
pages = "37--43",
journal = "Expert Review of Pharmacoeconomics & Outcomes Research",
issn = "1744-8379",
publisher = "Taylor and Francis Ltd.",
number = "1",

}

Cross-national drug price comparisons with economic weights in external reference pricing in Germany. / Mahlich, Joerg; Sindern, Joern; Suppliet, Moritz.

In: Expert Review of Pharmacoeconomics & Outcomes Research, Vol. 19, No. 1, 01.2019, p. 37-43.

Research output: Contribution to journalReview articleScientificpeer-review

TY - JOUR

T1 - Cross-national drug price comparisons with economic weights in external reference pricing in Germany

AU - Mahlich, Joerg

AU - Sindern, Joern

AU - Suppliet, Moritz

PY - 2019/1

Y1 - 2019/1

N2 - Background: Since 2012, the pharmaceutical reimbursement legislation in Germany has been applying external reference pricing that uses country-specific economic weights for foreign prices. However, the law does not specify technical details. Therefore, we develop a proposal how national income weights can be taken into consideration.Areas covered: We develop weighting schemes that draw on gross domestic product per capita and adjust for purchasing power parities, and exchange rates. In a second step, we populate the weighting schemes with economic data as well as with the price data for a pharmaceutical product (abiraterone acetate). Weighting the price of abiraterone acetate by gross domestic product per capita indicates potential price differentials of up to 43 percentage points across European prices in the German basket.Expert commentary: The weighting of foreign pharmaceutical prices by economic indicators, i.e. gross domestic product per capita, can capture economic differences across countries. It would also allow for differential Ramsey pricing which might foster innovation.

AB - Background: Since 2012, the pharmaceutical reimbursement legislation in Germany has been applying external reference pricing that uses country-specific economic weights for foreign prices. However, the law does not specify technical details. Therefore, we develop a proposal how national income weights can be taken into consideration.Areas covered: We develop weighting schemes that draw on gross domestic product per capita and adjust for purchasing power parities, and exchange rates. In a second step, we populate the weighting schemes with economic data as well as with the price data for a pharmaceutical product (abiraterone acetate). Weighting the price of abiraterone acetate by gross domestic product per capita indicates potential price differentials of up to 43 percentage points across European prices in the German basket.Expert commentary: The weighting of foreign pharmaceutical prices by economic indicators, i.e. gross domestic product per capita, can capture economic differences across countries. It would also allow for differential Ramsey pricing which might foster innovation.

KW - pharmaceutical prices

KW - reference pricing

KW - innovation

KW - cross-country price comparisons

KW - health policy

KW - health insurance

KW - regulation

U2 - 10.1080/14737167.2019.1527221

DO - 10.1080/14737167.2019.1527221

M3 - Review article

VL - 19

SP - 37

EP - 43

JO - Expert Review of Pharmacoeconomics & Outcomes Research

JF - Expert Review of Pharmacoeconomics & Outcomes Research

SN - 1744-8379

IS - 1

ER -